Panion's presentation at the investor meeting 14. December 2018
he CEO of Panion, Anja Holm, presented the progress and the plans for the company's development at the investor meeting held at Mangold offices in relation with the current share issue.
Panion's epilepsy project has just started the clinical phase with a pilot study in dogs.
Link to presentation: http://panion-animalhealth.com/2/wp-content/uploads/2018/12/Panion_20181214Stockholm.pdf
Link to emission-page: http://panion-animalhealth.com/emission/
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.
Panion is attracting interest from the agribusiness intelligence and animal health media Animal Pharm, where journalist Sian Lazell yesterday, 31.st of January 2019, noted the news on financing of the development program from Panion: https://bit.ly/2t1tgeK "Panion secures extra funding to back R&D. The financing round was carried out through the issuance of notes with warrants attached to Yorkville Advisors Global, that have a principal amount of SEK 100,000 each.
Panion Animal Health AB ("Panion") kallar på en andra tranche från den investeringsfond som förvaltas av Yorkville Advisors Global ("Yorkville").
Panion Animal Health AB ("Panion") draws down a second tranche from the investment fund managed by Yorkville Advisors Global ("Yorkville").
The rights issue in Panion Animal Health AB has been registered by the Swedish Companies Registration Office
The rights issue which was decided by the Board of Panion Animal Health AB, with the authorization of the Annual General Meeting of 29 May 2018, has now been registered by the Swedish Companies Registration Office. Shares and share capital after the registration by the Swedish Companies Registration Office amount to SEK 1,137,110.723254 divided into 24,399,487 shares.
Panion Animal Health AB
Marknadsplats: Spotlight Stock Market
Interim Report Q3 2018
2019-02-22 Delårsrapport Q4 2018